TU‐C‐201C‐03: Next Generation of Imaging Platforms: Clinical Validation of Nanomedicine

Keyphrases

• Nanoparticles 100%
• Clinical Validation 100%
• Imaging Platform 100%
• Nanomedicine 100%
• Molecular Imaging 80%
• Clinical Trials 40%
• Pharmacokinetics 40%
• Clinical Management 40%
• Cancer Therapy 20%
• Epitope 20%
• Cargo 20%
• Ligand Binding Specificity 20%
• Ligand Binding Affinity 20%
• Screening Tool 20%
• Evidence-based Guidelines 20%
• Clinical Practice Guidelines 20%
• Early Treatment 20%
• Phase I Clinical Trial 20%
• Imaging Techniques 20%
• Severe Disease 20%
• Early Diagnosis 20%
• Whole Blood 20%
• Picomolar Level 20%
• Early Indication 20%
• Relative Concentration 20%
• Clearance Rate 20%
• Non-invasive Imaging 20%
• Disease Treatment 20%
• Evidence-based Medicine 20%
• Blood Levels 20%
• Preclinical Animal Models 20%
• Nanotechnology 20%
• Pharmacokinetic Study 20%
• Biochemical Changes 20%
• Redirection 20%
• Low-affinity Binding Sites 20%
• Safety Study 20%
• Holy Grail 20%
• Moderate Disease 20%
• Physician Office 20%
• Present Challenges 20%
• Improved Control 20%
• Non-invasive Management 20%
• Biomarker Expression 20%
• Some Element 20%
• Compartmental Modeling 20%
• False Positive Reading 20%
• Modeling Tools 20%
• Fouling 20%
• Tissue Biomarkers 20%
• Management Tools 20%
• Small-molecule Probes 20%
• Robust Technology 20%
• Bioanalytics 20%
• Pathological Correlation 20%
• Quantitative Molecular Imaging 20%
• Bioelimination 20%
• Clearance Profile 20%
• Interfering Substances 20%
• Blood Constituents 20%
• Ambitious Targets 20%
• Nano Level 20%

Medicine and Dentistry

• Molecular Imaging 100%
• Nanomedicine 100%
• Nanoparticle 100%
• Clinical Trial 60%
• Pharmacokinetics 60%
• In Vitro 40%
• Clinical Management 40%
• Target Tissue 40%
• Binding Affinity 40%
• Diseases 40%
• Biological Marker 20%
• Cancer Therapy 20%
• Malignant Neoplasm 20%
• Epitope 20%
• Imaging Technique 20%
• Reproducibility 20%
• Early Diagnosis 20%
• False Positive Result 20%
• Clearance 20%
• Clinical Guideline 20%
• Evidence-Based Medicine 20%
• Buffer 20%
• Ligand Binding 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Nanoparticle 100%
• Nanomedicine 100%
• Clinical Trial 60%
• Pharmacokinetics 60%
• Malignant Neoplasm 40%
• Diseases 40%
• Biological Marker 20%
• Epitope 20%
• Buffer 20%